Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.40 |
| ▸ | PDE4A | P27815 | 8/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21713065 | 0.89 | SMO (0.40) | PDE10ASMO | |
| SCHEMBL276092 | 0.85 | GLP1R (0.38) | PDE10ASMO | |
| SCHEMBL275614 | 0.85 | CNR2 (0.38) | PDE10ASMO | |
| SCHEMBL276023 | 0.78 | PDE10A (0.37) | PDE10ASMO | |
| SCHEMBL275522 | 0.76 | GLP1R (0.38) | PDE10ASMO | |
| SCHEMBL2373792 | 0.75 | NPC1 (0.42) | PDE10A | |
| SCHEMBL16334101 | 0.74 | ALDH1A1 (0.46) | PDE10A | |
| SCHEMBL4421504 | 0.72 | PDE10A (0.94) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL25148426 | 0.72 | PDE10A (0.58) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL30331943 | 0.72 | PDE10A (0.58) | PDE10ACHRM3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765766-B2 | Pyrimidine derivatives which are antagonists of the vitronectin receptor | GALAPAGOS NV (BE) | 2014-07-01 | — | — | US | disclosed |
| EP-1747222-B1 | PYRIMIDINE DERIVATIVES ANTAGONISTS OF VITRONECTIN RECEPTOR | GALAPAGOS NV (BE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2368891-B1 | Pyrimidines derivatives as antagonists of the vitronectine receptors | GALAPAGOS NV (BE) | 2012-09-19 | — | — | EP | disclosed |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2012-05-10 | — | — | US | disclosed |
| US-8133896-B2 | Pyrimidine derivatives which are antagonist of the vitronectin receptor | GALAPAGOS NV (BE) | 2012-03-13 | — | — | US | disclosed |
| EP-2368891-A1 | Pyrimidines derivatives as antagonists of the vitronectine receptors | Galapagos SAS (FR) | 2011-09-28 | — | — | EP | disclosed |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2011-02-17 | — | — | US | disclosed |
| US-7846932-B2 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | GALAPAGOS SAS (FR) | 2010-12-07 | — | — | US | disclosed |
| US-20100041675-A1 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | GALAPAGOS SAS | 2010-02-18 | — | — | US | disclosed |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | PROSKELIA SAS | 2008-03-06 | — | — | US | disclosed |
| EP-1747222-A1 | PYRIMIDINE DERIVATIVES ANTAGONISTS OF VITRONECTIN RECEPTOR | Proskelia SAS (FR) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005123734-A1 | PYRIMIDINE DERIVATIVES ANTAGONISTS OF VITRONECTIN RECEPTOR | PROSKELIA SAS (FR) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041675-A1 | treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate | TBXA2R, GPR55, ADGRE5 | PDE10A 1311/4885CHRM3 119/4885PDE4A 919/4885 |
| US-20110039867-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONIST OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | PDE10A 2683/4885CHRM3 120/4885PDE4A 2325/4885 |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | PDE10A 2681/4885CHRM3 119/4885PDE4A 2281/4885 |
| US-20080058348-A1 | Bone disorders such as osteoporosis, tumors and cardiovascular disorders; 4-(2-carboxy-2-Boc-aminoethylamino)-6-piperidinopyrimidines such as tert-butyl 2-benzyloxycarbonylamino-3-[2,5-dimethoxy-6-(4-[1,8]naphthyridin-2-yl-piperidin-1-yl)pyrimidin-4-ylamino]-propionate | CALCR, PTH1R, CALCRL | PDE10A 1523/4885CHRM3 441/4885PDE4A 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.